세계의 골다공증 치료 시장 보고서(2025년)

Osteoporosis treatment encompasses medical interventions designed to manage and improve the condition of osteoporosis. This bone disease occurs when there is a decline in bone mass and mineral density, or when the composition and strength of bones change. The primary goals of osteoporosis treatment are to stop bone deterioration, reduce the risk of fractures, and enhance overall bone health.

Key pharmaceuticals involved in osteoporosis treatment include bisphosphonates, calcitonin, hormone therapy, selective estrogen receptor modulators (SERMs), parathyroid hormone-related protein (PTHrP) analog, and rank ligand (RANKL) inhibitor. Bisphosphonates, recognized for their efficacy in relieving bone discomfort associated with certain cancers and hypercalcemia, are pivotal in preventing osteoporotic fractures. These medications can be administered orally, through injections, and other modalities, with distribution channels spanning hospitals, retail pharmacies, stores, and online pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The osteoporosis treatment research report is one of a series of new reports from The Business Research Company that provides osteoporosis treatment market statistics, including the osteoporosis treatment industry's global market size, regional shares, competitors with osteoporosis treatment market share, detailed osteoporosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the osteoporosis treatment industry. This osteoporosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The osteoporosis treatment market size has grown steadily in recent years. It will grow from $13.96 billion in 2024 to $14.57 billion in 2025 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to aging population demographics, hormone replacement therapies, calcium and vitamin d supplementation, increased diagnostic tools, integration of digital health solutions.

The osteoporosis treatment market size is expected to see strong growth in the next few years. It will grow to $17.73 billion in 2029 at a compound annual growth rate (CAGR) of 5.0%. The growth in the forecast period can be attributed to rise in sedentary lifestyles, rising prevalence of secondary osteoporosis, virtual bone fracture clinics, gene therapy for osteoporosis, increased focus on men's bone health. Major trends in the forecast period include advancements in biologics, integration of artificial intelligence, blockchain in bone health records, integration of machine learning.

The forecast of 5.0% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder bone health management by inflating prices of denosumab biosimilars (India) and Dual-energy X-ray absorptiometry scan components (Belgium), resulting in delayed osteoporosis diagnoses and higher endocrinology testing costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence and incidence of osteoporosis are anticipated to drive the growth of the osteoporosis treatment market in the future. Osteoporosis is a bone disease that occurs when there are changes in bone strength and composition, or when there is a decline in bone mass and mineral density. Most osteoporosis medications work by slowing the deterioration of bones, while hormone-based treatments, such as estrogen, can help maintain bone density, particularly when started shortly after menopause. For example, in May 2022, Amgen, a US-based biopharmaceutical company, projected that the annual number of osteoporosis-related fractures could rise by 68%, reaching 3.2 million by 2040. Additionally, in April 2022, the National Library of Medicine reported that approximately 549,000 new fragility fractures are recorded annually in the UK, with one-third of these cases occurring in men. Due to the aging population, this figure is expected to increase by 19.6% by 2030. Consequently, the growing prevalence and incidence of osteoporosis are fueling the expansion of the osteoporosis treatment market.

The growth of the osteoporosis treatment market is fueled by the escalating healthcare expenditures. Healthcare expenditures encompass the total spending on healthcare services and products within a specific timeframe. Osteoporosis treatment contributes significantly to the rising healthcare costs, covering expenses for diagnostic tests, medications, rehabilitation services, and potential surgeries. In November 2022, the CIHI projected a 0.8% increase in total health spending in Canada, from $328 billion in 2021 to $331 billion in 2022, underscoring the market's expansion facilitated by the surge in healthcare expenditures.

Major companies in the osteoporosis treatment market are concentrating on the development of advanced injectable therapies to maintain their competitive edge. Injectable osteoporosis treatments are administered through injections to help prevent bone loss and lower fracture risk in individuals with osteoporosis. These treatments provide a direct approach to improving bone density and enhancing skeletal health. For example, in November 2023, Apotex Corp., a Canada-based pharmaceutical company, introduced Teriparatide Injection. This pre-filled pen is designed for single-patient use in the treatment of osteoporosis, featuring a concentration of 250 mcg/mL and offering 28 daily doses of 20 mcg each per pen. This product aims to improve access to affordable treatment for approximately 10 million Americans affected by osteoporosis. Its development highlights Apotex's commitment to producing complex generic medications, ensuring that patients have access to high-quality treatment.

Leading companies in the osteoporosis treatment market are strategically focusing on the development of derivative capsules, particularly those containing vitamin D3, to attain a competitive advantage. In December 2022, Chugai Pharmaceutical Co., Ltd., based in Tokyo, collaborated with Towa Pharmaceutical, a Japan-based counterpart, to launch 'Edirol Tablets 0.5 µg/0.75 µg.' These capsules, featuring an active vitamin D3 derivative, are tailored for the treatment of osteoporosis. Specifically designed to enhance bone and calcium metabolism, Edirol Tablets aim to reduce vertebral fractures and increase bone mineral density, exemplifying the companies' commitment to cutting-edge solutions.

In May 2023, Abiogen Pharma, an Italy-based specialist in osteoarticular and bone metabolism diseases, acquired a 97.09% stake in EffRx Pharmaceuticals. This strategic acquisition, conducted for an undisclosed amount, serves to strengthen Abiogen Pharma's global presence and underscores its dedication to bone health and rare diseases. EffRx Pharmaceuticals, headquartered in Switzerland, possesses a portfolio that includes products for the treatment of postmenopausal osteoporosis, aligning with Abiogen Pharma's broader objectives in the field.

Major companies operating in the osteoporosis treatment market include Pfizer Inc., F. Hoffmann La Roche Ltd., Merck and Co Inc., AbbVie Inc., Novartis AG, GlaxoSmithKline Pharmaceutical Ltd., Takeda Pharmaceutical Company, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Asahi Kasei Corporation, AstraZeneca Plc., Viatris Inc., Teva Pharmaceuticals Industries Ltd., Daiichi Sankyo Company Ltd, Dr. Reddy's Laboratories, Gedeon Richter Plc., Celltrion Inc., Luye Pharma Group, Ligand Pharmaceuticals Incorporated, Radius Health Inc., Haoma Medica Ltd., EffRx Pharmaceuticals SA

North America was the largest region in the osteoporosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the osteoporosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the osteoporosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The osteoporosis treatment market consists of revenues earned by entities by providing osteoporosis services such as physical therapy and rehabilitation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The osteoporosis treatment market also includes sales of alendronate, risedronate, Ibandronate, and zoledronic acid. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Osteoporosis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on osteoporosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for osteoporosis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The osteoporosis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Bisphosphonates; Calcitonin; Hormone Therapy; Selective Estrogen Receptor Modulators (SERMs); Parathyroid Hormone-Related Protein (PTHrP) Analog; Rank Ligand (RANKL) Inhibitor
• 2) By Route Of Administration: Oral; Injectable; Other Routes
• 3) By Distribution Channel: Hospitals; Retail Pharmacies And Stores; Online Pharmacies
• Subsegments:
• 1) By Bisphosphonates: Alendronate; Risedronate; Ibandronate; Zoledronic Acid
• 2) By Calcitonin: Salmon Calcitonin; Synthetic Calcitonin Formulations
• 3) By Hormone Therapy: Estrogen Replacement Therapy; Combination Hormone Therapy (Estrogen And Progesterone)

4) By Selective Estrogen Receptor Modulators (SERMs); Raloxifene; Bazedoxifene

• 5) By Parathyroid Hormone-Related Protein (PTHrP) Analog: PTH Analog (Teriparatide); Other PTHrP Analogues
• 6) By Rank Ligand (RANKL) Inhibito: Denosumab
• Companies Mentioned: Pfizer Inc.; F. Hoffmann La Roche Ltd.; Merck and Co Inc.; AbbVie Inc.; Novartis AG; GlaxoSmithKline Pharmaceutical Ltd.; Takeda Pharmaceutical Company; Eli Lilly and Company; Amgen Inc.; Novo Nordisk A/S; Asahi Kasei Corporation; AstraZeneca Plc.; Viatris Inc.; Teva Pharmaceuticals Industries Ltd.; Daiichi Sankyo Company Ltd; Dr. Reddy's Laboratories; Gedeon Richter Plc.; Celltrion Inc.; Luye Pharma Group; Ligand Pharmaceuticals Incorporated; Radius Health Inc.; Haoma Medica Ltd.; EffRx Pharmaceuticals SA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Osteoporosis Treatment Market Characteristics

3. Osteoporosis Treatment Market Trends And Strategies

4. Osteoporosis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Osteoporosis Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Osteoporosis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Osteoporosis Treatment Market Growth Rate Analysis
• 5.4. Global Osteoporosis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Osteoporosis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Osteoporosis Treatment Total Addressable Market (TAM)

6. Osteoporosis Treatment Market Segmentation

• 6.1. Global Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bisphosphonates
• Calcitonin
• Hormone Therapy
• Selective Estrogen Receptor Modulators (SERMs)
• Parathyroid Hormone-Related Protein (PTHrP) Analog
• Rank Ligand (RANKL) Inhibitor
• 6.2. Global Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Other Routes
• 6.3. Global Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Retail Pharmacies And Stores
• Online Pharmacies
• 6.4. Global Osteoporosis Treatment Market, Sub-Segmentation Of Bisphosphonates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alendronate
• Risedronate
• Ibandronate
• Zoledronic Acid
• 6.5. Global Osteoporosis Treatment Market, Sub-Segmentation Of Calcitonin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Salmon Calcitonin
• Synthetic Calcitonin Formulations
• 6.6. Global Osteoporosis Treatment Market, Sub-Segmentation Of Hormone Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Estrogen Replacement Therapy
• Combination Hormone Therapy (Estrogen And Progesterone)
• 6.7. Global Osteoporosis Treatment Market, Sub-Segmentation Of Selective Estrogen Receptor Modulators (SERMs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Raloxifene
• Bazedoxifene
• 6.8. Global Osteoporosis Treatment Market, Sub-Segmentation Of Parathyroid Hormone-Related Protein (PTHrP) Analog, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PTH Analog (Teriparatide)
• Other PTHrP Analogues
• 6.9. Global Osteoporosis Treatment Market, Sub-Segmentation Of Rank Ligand (RANKL) Inhibito, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Denosumab

7. Osteoporosis Treatment Market Regional And Country Analysis

• 7.1. Global Osteoporosis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Osteoporosis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Osteoporosis Treatment Market

• 8.1. Asia-Pacific Osteoporosis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Osteoporosis Treatment Market

• 9.1. China Osteoporosis Treatment Market Overview
• 9.2. China Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Osteoporosis Treatment Market

• 10.1. India Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Osteoporosis Treatment Market

• 11.1. Japan Osteoporosis Treatment Market Overview
• 11.2. Japan Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Osteoporosis Treatment Market

• 12.1. Australia Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Osteoporosis Treatment Market

• 13.1. Indonesia Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Osteoporosis Treatment Market

• 14.1. South Korea Osteoporosis Treatment Market Overview
• 14.2. South Korea Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Osteoporosis Treatment Market

• 15.1. Western Europe Osteoporosis Treatment Market Overview
• 15.2. Western Europe Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Osteoporosis Treatment Market

• 16.1. UK Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Osteoporosis Treatment Market

• 17.1. Germany Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Osteoporosis Treatment Market

• 18.1. France Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Osteoporosis Treatment Market

• 19.1. Italy Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Osteoporosis Treatment Market

• 20.1. Spain Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Osteoporosis Treatment Market

• 21.1. Eastern Europe Osteoporosis Treatment Market Overview
• 21.2. Eastern Europe Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Osteoporosis Treatment Market

• 22.1. Russia Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Osteoporosis Treatment Market

• 23.1. North America Osteoporosis Treatment Market Overview
• 23.2. North America Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Osteoporosis Treatment Market

• 24.1. USA Osteoporosis Treatment Market Overview
• 24.2. USA Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Osteoporosis Treatment Market

• 25.1. Canada Osteoporosis Treatment Market Overview
• 25.2. Canada Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Osteoporosis Treatment Market

• 26.1. South America Osteoporosis Treatment Market Overview
• 26.2. South America Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Osteoporosis Treatment Market

• 27.1. Brazil Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Osteoporosis Treatment Market

• 28.1. Middle East Osteoporosis Treatment Market Overview
• 28.2. Middle East Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Osteoporosis Treatment Market

• 29.1. Africa Osteoporosis Treatment Market Overview
• 29.2. Africa Osteoporosis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Osteoporosis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Osteoporosis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Osteoporosis Treatment Market Competitive Landscape And Company Profiles

• 30.1. Osteoporosis Treatment Market Competitive Landscape
• 30.2. Osteoporosis Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck and Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Osteoporosis Treatment Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline Pharmaceutical Ltd.
• 31.2. Takeda Pharmaceutical Company
• 31.3. Eli Lilly and Company
• 31.4. Amgen Inc.
• 31.5. Novo Nordisk A/S
• 31.6. Asahi Kasei Corporation
• 31.7. AstraZeneca Plc.
• 31.8. Viatris Inc.
• 31.9. Teva Pharmaceuticals Industries Ltd.
• 31.10. Daiichi Sankyo Company Ltd
• 31.11. Dr. Reddy's Laboratories
• 31.12. Gedeon Richter Plc.
• 31.13. Celltrion Inc.
• 31.14. Luye Pharma Group
• 31.15. Ligand Pharmaceuticals Incorporated

32. Global Osteoporosis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Osteoporosis Treatment Market

34. Recent Developments In The Osteoporosis Treatment Market

35. Osteoporosis Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Osteoporosis Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Osteoporosis Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Osteoporosis Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer